Periodic and transient insomnia. Antihistamines for systemic use.
active substance: 1 tablet contains 15 mg doxylamine succinate;
excipients: lactose, monohydrate; magnesium stearate; sodium croscarmellose, microcrystalline cellulose;
casing: Opadry II White film coating mixture: hypromellose (hydroxypropyl methylcellulose); lactose, monohydrate; polyethylene glycol (macrogol); titanium dioxide (E 171); triacetin.
Doxylamine succinate is a blocker of H1-histamine receptors of the ethanolamine class, which has a sedative and atropine-like effect. It has been shown to reduce the time it takes to fall asleep and also to improve the duration and quality of sleep.
Intermittent and transient insomnia.
Hypersensitivity to doxylamine succinate or other antihistamines.
Patient history or family history of closed-angle glaucoma.
Urethroprostatic disorders with a risk of urinary retention.
Method of administration and dosage
For oral administration. Take 15-30 minutes before bedtime.
The recommended dose is 7.5-15 mg per day (1 / 2-1 tablet per day). If necessary, the dose can be increased to 30 mg per day (2 tablets per day).
Elderly patients and patients with renal or hepatic insufficiency are advised to reduce the dose.
The duration of the course of treatment is 2-5 days.
If insomnia persists for more than 5 days, it is necessary to consult a doctor regarding the appropriateness of further use of the drug.
Do not administer the medicine to children under 15 years of age.
The first signs of acute poisoning are drowsiness and signs of anticholinergic effects: agitation, dilated pupils, accommodation paralysis, dry mouth, redness of the face and neck, hyperthermia, sinus tachycardia. Delirium, hallucinations, and athetosis are more common in children; sometimes they are harbingers of seizures – rare complications of severe poisoning. Even if seizures do not occur, acute doxylamine poisoning sometimes causes rhabdomyolysis, which can be complicated by acute renal failure. This muscle disorder is common and requires systematic screening by measuring creatine phosphokinase activity.
Treatment is symptomatic. At an early start of treatment, it is recommended to use activated carbon (50 g for adults, 1 g / kg for children).
Anticholinergic effects rarely develop: constipation, dry mouth, poor accommodation, palpitations.
Daytime sleepiness: if this effect develops, the dose must be reduced.
Allergic reactions are possible, including skin rash, itching.
Store in its original packaging at a temperature not exceeding 25 ° C.
Keep out of the reach of children.